TAK

Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Peers: SNY BMY GSK ABBV AZN JNJ LLY MRK NVS PFE

| Held by: FVD PPH AVDE APIE VEU BDYN JSTC AADR GINX AVSD

Scroll to Statements

Index	-
Market Cap	52.33B
Enterprise Value	83.02B
Income	-896.45M
Sales	29.91B
Book/sh	14.78
Cash/sh	1.18
Dividend Est.	0.64 (3.84%)
Dividend TTM	0.63 (3.80%)
Dividend Ex-Date	Mar 31, 2026
Dividend Gr. 3/5Y	3.45% -4.49%
Payout	-
Employees	47029
IPO	Mar 06, 2008

P/E	-
Forward P/E	27.18
PEG	1.09
P/S	1.75
P/B	1.12
P/C	13.99
P/FCF	10.37
EV/EBITDA	8.97
EV/Sales	2.78
Quick Ratio	0.60
Current Ratio	1.09
Debt/Eq	0.74
LT Debt/Eq	0.66
Option/Short	Yes / Yes

EPS (ttm)	-0.29
EPS next Y	0.61
EPS next Q	0.16
EPS this Y	-4.47%
EPS next Y	65.66%
EPS next 5Y	25.04%
EPS past 3/5Y	- -
Sales past 3/5Y	0.19% -0.17%
EPS Y/Y TTM	-225.21%
Sales Y/Y TTM	-0.47%
EPS Q/Q	-246.69%
Sales Q/Q	0.93%
Earnings	May 13 AMC
EPS/Sales Surpr.	34.75% -3.01%

Insider Own	0.00%
Insider Trans	-
Inst Own	3.12%
Inst Trans	-1.53%
ROA	-0.93%
ROE	-1.93%
ROIC	-1.16%
Gross Margin	53.45%
Oper. Margin	14.47%
Profit Margin	-3.00%
SMA20	3.07%
SMA50	2.63%
SMA200	2.96%
Trades

Shs Outstand	3.16B
Shs Float	3.16B
Short Float	0.17%
Short Ratio	1.76
Short Interest	5.26M
52W High	18.90 -12.36%
52W Low	12.99 27.48%
Volatility	1.10% 1.28%
ATR (14)	0.27
RSI (14)	57.80
Beta	-0.04
Rel Volume	0.50
Avg Volume	2.98M
Volume	1,503,758

Perf Week	-1.25%
Perf Month	5.34%
Perf Quarter	-10.29%
Perf Half Y	4.15%
Perf YTD	6.22%
Perf Year	11.59%
Perf 3Y	6.56%
Perf 5Y	-1.08%
Perf 10Y	-22.92%
Recom	1.93
Target Price	18.66
Prev Close	16.61
Price	16.56
Change	-0.30%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-08-26	Upgrade	Bernstein	Mkt Perform → Outperform
Jan-13-26	Resumed	Morgan Stanley	Overweight
Apr-02-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Mar-16-23	Upgrade	BofA Securities	Neutral → Buy	$20
Jul-19-22	Upgrade	Cowen	Market Perform → Outperform	$21 → $24
Oct-07-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Apr-19-21	Downgrade	JP Morgan	Overweight → Neutral
Nov-01-19	Initiated	Cowen	Market Perform	$19.50
Aug-15-19	Downgrade	Daiwa Securities	Outperform → Neutral

Jul-02-26 06:32AM	Insilico Medicine, Takeda partner on AI-driven drug discovery (Pharmaceutical Technology) +5.14%
Jun-26-26 05:46AM	Alkermes incoming CEO has a plan to outplay Lilly and Takeda (BioPharma Dive)
Jun-24-26 03:05AM	Takeda Announces New Assignments of Directors and Appointment of Julie Kim as Representative Director, President and CEO (Business Wire)
Jun-15-26 12:00PM	New Pivotal Study Data Show Takedas Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1 (Business Wire)
Jun-11-26 03:00AM	Takedas $4B TYK2 drug tops Bristol Myers Sotyktu in head-to-head test (BioPharma Dive)
04:30PM	Loading…
Jun-09-26 04:30PM	U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease (Business Wire)
Jun-05-26 04:55AM	GSK, Takeda and others notch key clinical wins in tough-to-treat diseases (Pharma Voice)
Jun-04-26 05:22AM	Otsuka showcases kidney drug data; Pfizer cuts an AI deal (BioPharma Dive)
May-20-26 07:15AM	Takeda faces $885m hit after landmark pay-for-delay lawsuit verdict (Pharmaceutical Technology)
06:43AM	Immunovants potential autoimmune blockbuster; Waves RNA editing update (BioPharma Dive)
May-18-26 05:51PM	Attorneys at Hagens Berman Announce $474M Win in Amitiza Jury Trial Against Takeda (Business Wire)
May-15-26 07:36AM	Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workers (BioPharma Dive)
May-13-26 02:38AM	Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results (Business Wire)
May-04-26 08:00AM	Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID) (Business Wire)
Apr-14-26 08:02PM	Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now? (Quartz)
07:07AM	Loading…
Apr-06-26 07:07AM	FDA floats new clinical trial reforms; Takeda punts Denali brain drug (BioPharma Dive)
Mar-28-26 03:00PM	Takedas Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care (Business Wire)
Mar-08-26 04:49PM	These 8 drugs could help fight dementia - and they're already on the market (MarketWatch)
12:01PM	FDA Grants Priority Review for Takeda (TAK) and Protagonist's Rusfertide in PV Treatment (Insider Monkey)
Mar-02-26 02:00AM	Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera (Business Wire)
Feb-28-26 12:35PM	Keros Therapeutics Touts Rinvatercept DMD Trial Start, Eyes ALS Phase II Talks at Oppenheimer Conference (MarketBeat)
Feb-27-26 09:02AM	DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in Focus (Zacks)
Feb-26-26 08:30AM	Novavax, Inc. Q4 2025 Earnings Call Summary (Moby)
Feb-24-26 09:35AM	Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity (PR Newswire)
Feb-23-26 07:39AM	Novo Nordisk flags board members for re-election amid restructuring efforts (Pharmaceutical Technology)
Feb-20-26 10:17AM	Takeda Shares Down After Entyvio Shows Strong Results In Ulcerative Colitis Trial In Children, Shows Potential To Address Treatment Gaps (Benzinga)
Feb-19-26 12:00PM	Positive Phase 3 Data Demonstrate Potential for ENTYVIO (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis (Business Wire)
Feb-18-26 10:10AM	FDA Grants Breakthrough Status To Johnson & Johnson's Cancer Drug For Advanced Head and Neck Cancer (Benzinga)
09:39AM	Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings? (Zacks)
Feb-11-26 04:33AM	Evommune rockets on eczema data; AstraZeneca advances GLP-1 pill (BioPharma Dive)
08:30AM	Loading…
Feb-10-26 08:30AM	Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market (PR Newswire)
05:30AM	Takeda and Iambic announce $1.7bn deal to advance small molecule programmes (Pharmaceutical Technology)
03:15AM	U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takedas Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1 (Business Wire)
Feb-09-26 12:59PM	Takeda Taps AI Startup Iambic In $1.7 Billion+ Deal To Speed Up Drug Discovery (Benzinga)
08:07AM	Takeda deepens AI drug discovery push with $1.7 billion Iambic deal (Reuters)
03:00AM	Takeda, Iambic partner in latest pharma AI push (BioPharma Dive)
Jan-31-26 09:36AM	Is Takeda Pharmaceutical Company Limited (TAK) One of the Best Healthcare Stocks to Buy for 2026? (Insider Monkey)
Jan-29-26 09:11AM	Takeda Flags Vyvanse Hit, Lifts 2025 Profit Guidance On Cost Control (Benzinga)
08:37AM	Takeda Pharmaceutical Q3 Earnings Call Highlights (MarketBeat)
01:37AM	Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches Ahead (Business Wire)
Jan-28-26 07:48AM	CMS selects next batch of 15 high-cost medicines for third negotiation cycle (Pharmaceutical Technology)
05:51AM	Medicare Targets 15 High-Profile Drugs In Third Price Negotiation Cycle (Benzinga)
Jan-22-26 09:13AM	ADMA Gains 13.8% in Three Months: More Upside Potential for 2026? (Zacks)
07:45AM	Takeda Announces U.S. Availability of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1 (Business Wire)
Jan-15-26 06:19PM	JPM26: Matrix-M Technology is central to Novavaxs strategy (Pharmaceutical Technology)
09:14AM	KROS Stock Surges 85.6% in a Year: More Upside Potential in 2026? (Zacks)
Jan-14-26 12:10AM	Ascentage: Partnership With Takeda Going Well (Bloomberg)
Jan-07-26 01:01PM	Denali Therapeutics Unveils Portfolio Goals for 2026, Stock Up (Zacks)
Jan-06-26 07:05AM	Takeda and Protagonist seek FDA approval for rusfertide to treat PV (Pharmaceutical Technology)
06:50AM	Alumis soars as TYK2 drug hits mark in psoriasis trials (BioPharma Dive)
Jan-05-26 07:00AM	Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV) (Business Wire)
Dec-19-25 07:00AM	Cambridge property takes novel approach to quality in life sciences sector (Facilities Dive)
Dec-18-25 04:45AM	Takeda says $4B TYK2 drug succeeds in large psoriasis studies (BioPharma Dive)
03:00AM	Takedas Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment (Business Wire)
Dec-06-25 09:30AM	Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera (Business Wire)
Dec-05-25 09:56AM	Denali Enters Into a $275M Funding Deal With Royalty Pharma (Zacks)
05:19AM	Takeda and Innovent fulfil close conditions for ADC and IO therapies (Pharmaceutical Technology)
Nov-07-25 01:23PM	DNLI Posts Narrower-Than-Expected Q3 Loss, Advances MPS IIIA Drug (Zacks)
Nov-03-25 07:00AM	New Phase 3 Data Show Takedas Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization (Business Wire)
Oct-30-25 03:04AM	Takeda Reports First Half FY2025 Results, with Business Fundamentals Tracking as Planned. Updates Full Year Outlook to Reflect FX Impact and Pipeline Impairment. On Track for Multiple Regulatory Filings This Fiscal Year (Business Wire)
Oct-22-25 06:33AM	Chinas Innovent Strikes Cancer Drug Deal With Takeda for Up to $11.4 Billion (The Wall Street Journal)
Oct-21-25 05:53AM	Takeda Pharmaceutical Company (TAK) Signs a Research Partnership with Nabla Bio (Insider Monkey)
Oct-10-25 11:13AM	Johnson & Johnson in Talks to Buy Protagonist Therapeutics (The Wall Street Journal)
Sep-23-25 06:04PM	20,000 + Takeda Employees Voted to Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems in 94 Countries (Business Wire)
Sep-17-25 05:45AM	5 Best High-Yield Dividend Stocks to Buy Now (Motley Fool)
Sep-16-25 08:00AM	Takeda and VELA to Ship Medicines Across the Atlantic Using First-of-its-Kind Wind-Powered Trimaran (Business Wire)
Sep-08-25 03:00AM	Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025 (Business Wire)
Sep-05-25 08:45PM	U.S. FDA Approves Expanded Indication for VONVENDI [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease (Business Wire)
Aug-28-25 04:55AM	Takeda Pharmaceutical Company Limited (TAK) Advances ?d T Cell Cancer Treatments (Insider Monkey)
Aug-08-25 01:18AM	Cosmo and Takeda Renew Strategic Manufacturing Agreement for Global Supply of Oral Treatment for Ulcerative Colitis (Newsfile)
Jul-30-25 02:41AM	Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression (Business Wire) -5.03%
Jul-21-25 04:12PM	Why Alkermes Tumbled On Its Positive Narcolepsy Study (Investor's Business Daily)
01:29PM	Alkermes Offers The Next Proof Point For Its Narcolepsy Approach. Stock Dives. (Investor's Business Daily)
08:00AM	Takeda Receives FDA 510(k) Clearance for HyHubTM and HyHubTM Duo Devices to Simplify HYQVIA Administration (Business Wire)
Jul-17-25 08:24AM	Improving Margins, Cash Flow Strength, and an Undervalued Opportunity (GuruFocus.com)
Jul-15-25 09:10AM	Takeda Pharmaceutical (TAK) Gets GAMMAGARD LIQUID ERC Approved by FDA (Insider Monkey)
Jul-14-25 03:00AM	Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1 (Business Wire)
Jul-10-25 09:11AM	KALV Stock Moves More Than 30% in a Week: What Is Driving This Rally? (Zacks)
Jun-30-25 08:00AM	Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1 (Business Wire)
Jun-27-25 08:11AM	Will Strong Asceniv Sales Drive ADMA Biologics Further? (Zacks)
Jun-25-25 11:13AM	Ocular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last? (Zacks)
08:54AM	ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today? (Zacks)
03:07AM	Takeda Announces New Assignments of Directors (Business Wire)
Jun-24-25 03:09PM	Protagonist Therapeutics, Takeda Pharmaceutical Announce Positive Phase 3 Rusfertide Results for Polycythemia Vera (Insider Monkey)
Jun-16-25 01:06PM	ADMA Looks to Expand Asceniv's Label: Will This Boost Sales? (Zacks)
Jun-06-25 10:40AM	ADMA Stock Gains 17% in Three Months: Buy, Sell or Hold? (Zacks)
Jun-04-25 04:47AM	EC approves Takeda ADC plus chemo for stage IIb Hodgkins lymphoma (Pharmaceutical Technology)
Jun-03-25 10:12AM	European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD (Business Wire)
Jun-01-25 08:00AM	Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera (Business Wire)
May-27-25 07:30AM	Takeda and Nature Announce Call for Applications Now Open for 2026 Innovators in Science Award (Business Wire)
May-14-25 05:03PM	The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1 (Business Wire)
May-12-25 04:28AM	Pharmaceutical Stocks Tumble on Trump Plan to Cut US Drug Prices (Bloomberg)
04:18AM	Trump Vows US Drug Price Cuts of Up to 80% in Industry Blow (Bloomberg)
May-09-25 03:00PM	Top 4 GARP Stocks With Attractive PEG Ratios to Watch (Zacks)
May-08-25 01:26PM	ADMA's Q1 Earnings and Revenues Miss: Buy, Sell or Hold the Stock? (Zacks) -5.25%
02:36AM	Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress (Business Wire)
May-07-25 12:06PM	Takeda Pharmaceutical FY Earnings Preview (Seeking Alpha)
12:00PM	Takeda Pharmaceutical Co. (TAK) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
09:40AM	Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock? (Zacks)
09:15AM	What To Expect From Takeda Pharmaceutical Co Ltd (TSE:4502) Q4 2024 Earnings (GuruFocus.com)

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following business divisions: Gastrointestinal Diseases, Rare Diseases, Plasma-Derived Therapies, Oncology, Vaccines, and Neuroscience The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

CFO & DirectorMr. Milano Furuta

Ph.D.Dr. Andrew S. Plump M.D.

CEOMs. So-Young Kim

Chair of Management BoardDr. Seigo Izumo

Member of Management BoardMr. Haruhiko Hirate

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	SEC Form 4
Lauren Rusckowski Duprey	Chief Human Resources Officer	Dec 09 '25	Proposed Sale	14.22	29,619	421,182	Dec 09 06:05 AM
Teresa Marie Bitetti	President, Global Oncology Bus	Dec 05 '25	Proposed Sale	14.28	87,023	1,242,688	Dec 05 06:08 AM
Giles Richard Platford	President, Plasma-Derived Ther	Dec 04 '25	Proposed Sale	14.31	58,421	836,005	Dec 04 06:02 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Takeda Pharmaceutical Co ADR

Upgrade your Finviz experience